Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
COMMENTARY
Will New Economic Security Bill Contribute to Ensuring Stable Drug Supplies?
The Japanese government is drafting an economic security bill it intends to submit to the Diet in late February. The draft bill aims to promote efforts to enhance supply chains for resources essential to people’s lives such as drugs, with…
To read the full story
Related Article
- MHLW Details Plan to Ensure Stable Supplies of β-Lactam Antibiotics
January 24, 2023
- Japan Designates Antibiotics as Key Resources for Economic Security
December 21, 2022
- Govt to Designate 4 β-Lactam Antibiotics as Key Resources by Year-End
November 18, 2022
- Govt Plans to Designate Key Resources Before End of Year: Minister
October 4, 2022
- Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
- Supply Chain Clause of Economic Security Law Now in Effect
August 2, 2022
- Guidelines for Securing Key Resources Endorsed by LDP, Up for Cabinet Approval
July 20, 2022
- All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
- Japan Govt Promulgates Economic Security Law
May 19, 2022
- Japan Enacts Economic Security Law; Supply Chain Clauses to Take Effect in 9 Months after Promulgation
May 12, 2022
- Lower House OKs Economic Security Bill
April 8, 2022
- PM Vows Effective Supply Chain Surveys as Economic Security Bill Enters Diet
March 18, 2022
- Economic Security Bill to Enter Diet Deliberations on March 17
March 17, 2022
- Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
March 15, 2022
- Japan Cabinet OKs Draft Economic Security Bill
February 28, 2022
- Key Resource Suppliers to Be Fined for False Reporting: Draft Economic Security Bill
February 17, 2022
- Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
COMMENTARY
- Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
- Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
- Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
December 10, 2024
- Japan Needs Transparent Debates amid Growing “No” to Off-Year Revisions
December 2, 2024
- MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…